I care deeply because this chronic disease is mine. It lives inside me. It’s radically changed my life and the life of my ...

DelveInsight's "FABHALTA Market Size, Forecast, and Market Insight Report" highlights the details around FABHALTA, an oral complement factor B inhibitor used to treat adults with paroxysmal nocturnal ...

Federal investigators traced the cases back to a single grower, but the Food and the Drug Administration didn't disclose the ...

ONE of the UK’s largest ever E.coli outbreaks, which saw 259 people fall ill and 75 hospitalised, was linked to salad leaves, ...

FOREST, Va. (WSET) — In January, 3-year-old Ryker McCracken was hospitalized with a life-threatening condition. Forest ...

An NBC News investigation found that there was a deadly E. coli outbreak linked to romaine lettuce at the end of 2024, but ...

An E. Coli outbreak in November killed one person and sickened at least 88 more. The FDA did not name a culprit, but victims ...

The parents of Colton George, who is still recovering from kidney failure, say they want the FDA to release which companies ...

The lawsuits were filed on behalf of two children and one adult woman who suffered from hemolytic uremic syndrome (HUS), a ...

“Individuals living with rare diseases, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis, often have limited access to life ...

With future approvals of FABHALTA, the market size is expected to expand significantly in the coming years, driven by its potential to address unmet medical needs across multiple conditions ...